1921
Volume 86, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Visceral leishmaniasis (VL) is responsible for substantial morbidity and mortality and current available treatments have many limitations. The ability of VL infection to generate life-long immunity offers promise for the development of a VL vaccine. A VL vaccine candidate has recently completed phase I clinical trials. We constructed a computer simulation model to determine the potential economic value of a VL vaccine in the endemic region of Bihar state, India. Results found a potential vaccine to be cost-effective (and in many cases economically dominant, i.e., saving costs and providing health benefits) throughout a wide range of vaccination costs and vaccine efficacies, and VL risks. Overall, our study strongly supports the continued development of a VL vaccine.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2012.10-0415
2012-03-01
2020-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/86/3/417.html?itemId=/content/journals/10.4269/ajtmh.2012.10-0415&mimeType=html&fmt=ahah

References

  1. Hotez PJ, Ferris MT, 2006. The antipoverty vaccines. Vaccine 24: 57875799.[Crossref]
    [Google Scholar]
  2. Vanlerberghe V, Diap G, Guerin PJ, Meheus F, Gerstl S, Van der Stuyft P, Boelaert M, 2007. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop Med Int Health 12: 274283.[Crossref]
    [Google Scholar]
  3. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 2532.
    [Google Scholar]
  4. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, Alam D, Kenah E, Amann J, Islam M, Wagatsuma Y, Haque R, Breiman RF, Maguire JH, 2003. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg 69: 624628.
    [Google Scholar]
  5. Meheus F, Boelaert M, Baltussen R, Sundar S, 2006. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health 11: 17151724.[Crossref]
    [Google Scholar]
  6. Joshi A, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A, 2008. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 45: 105111.
    [Google Scholar]
  7. World Health Organization, 2007. WHO Special Programme for Research and Training in Tropical Diseases (TDR): research to support the elimination of visceral leishmaniasis. Geneva: WHO.
    [Google Scholar]
  8. Berman J, 2009. ABLE: a new and improved amphotericin B for visceral leishmaniasis? Am J Trop Med Hyg 80: 689690.
    [Google Scholar]
  9. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 11041107.[Crossref]
    [Google Scholar]
  10. Kumar V, Kesari S, Kumar AJ, Dinesh DS, Ranjan A, Prasad M, Sinha NK, Kumar R, Das P, 2009. Vector density and the control of kala-azar in Bihar, India. Mem Inst Oswaldo Cruz 104: 10191022.[Crossref]
    [Google Scholar]
  11. Kumar V, Kesari S, Dinesh DS, Tiwari AK, Kumar AJ, Kumar R, Singh VP, Das P, 2009. A report on the indoor residual spraying (IRS) in the control of Phlebotomus argentipes, the vector of visceral leishmaniasis in Bihar (India): an initiative towards total elimination targeting 2015 (Series-1). J Vector Borne Dis 46: 225229.
    [Google Scholar]
  12. Joshi AB, Banjara MR, Pokhrel S, Jimba M, Singhasivanon P, Ashford RW, 2006. Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities. Kathmandu Univ Med J 4: 488496.
    [Google Scholar]
  13. Kedzierski L, 2010. Leishmaniasis vaccine: where are we today? J Glob Infect Dis 2: 177185.[Crossref]
    [Google Scholar]
  14. Nagill R, Kaur S, 2011. Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 11: 14641488.[Crossref]
    [Google Scholar]
  15. Coler RN, Reed SG, 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244249.[Crossref]
    [Google Scholar]
  16. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM, 2009. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28: 329337.[Crossref]
    [Google Scholar]
  17. Olliaro P, Darley S, Laxminarayan R, Sundar S, 2009. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health 14: 918925.[Crossref]
    [Google Scholar]
  18. 2008. Open-Label Safety Study of Three-Antigen Leishmania Polyprotein with Adjuvant MPL-SE in Healthy Adults in India.Available at: http://www.ClinicalTrials.gov. Accessed June 5, 2010.
    [Google Scholar]
  19. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG, 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75: 46484654.[Crossref]
    [Google Scholar]
  20. Lee BY, Burke DS, 2010. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28: 28062809.[Crossref]
    [Google Scholar]
  21. World Health Organization, 2008. Global Health Observatory: World Health Organization. Geneva: WHO.
    [Google Scholar]
  22. Bern C, Maguire JH, Alvar J, 2008. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.[Crossref]
    [Google Scholar]
  23. Ahluwalia IB, Bern C, Wagatsuma Y, Costa C, Chowdhury R, Ali M, Amann J, Haque R, Breiman R, Maguire JH, 2004. Visceral leishmaniasis: consequences to women in a Bangladeshi community. J Womens Health (Larchmt) 13: 360364.[Crossref]
    [Google Scholar]
  24. Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, Bista MB, 2000. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 63: 184188.
    [Google Scholar]
  25. Salotra P, Singh R, 2006. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res 123: 295310.
    [Google Scholar]
  26. Ministry of Finance Government of India, 2010. Economics Survey 2009–2010. Available at: http://indiabudget.nic.in/es2009-10/esmain.htm. Accessed June 3, 2010.
    [Google Scholar]
  27. Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, Kumar N, Pandey K, Das P, 2010. Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med Hyg 82: 911.[Crossref]
    [Google Scholar]
  28. Khalil EA, Zijlstra EE, Kager PA, El Hassan AM, 2002. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop Med Int Health 7: 3544.[Crossref]
    [Google Scholar]
  29. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A, 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93: 319323.[Crossref]
    [Google Scholar]
  30. Piscopo TV, Mallia Azzopardi C, 2007. Leishmaniasis. Postgrad Med J 83: 649657.
    [Google Scholar]
  31. ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, Ritmeijer K, 2009. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg 80: 929934.
    [Google Scholar]
  32. Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, O'Keeffe C, Davidson RN, 2006. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg 74: 7680.
    [Google Scholar]
  33. Sundar S, Singh RK, Maurya R, Kumar B, Chhabra A, Singh V, Rai M, 2006. Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg 100: 533537.[Crossref]
    [Google Scholar]
  34. Sundar S, Chatterjee M, 2006. Visceral leishmaniasis—current therapeutic modalities. Indian J Med Res 123: 345352.
    [Google Scholar]
  35. Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW, 2006. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol 44: 251253.[Crossref]
    [Google Scholar]
  36. Roy P, Noad R, 2008. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 4: 512.[Crossref]
    [Google Scholar]
  37. Maltezou HC, 2010. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010: 617521.
    [Google Scholar]
  38. Sarnoff R, Desai J, Desjeux P, Mittal A, Topno R, Siddiqui NA, Pandey A, Sur D, Das P, 2010. Visceral Leishmaniasis Supplement: The Economic Impact of Visceral Leishmaniasis on Rural Households in One Endemic District of Bihar, India. San Francisco, CA: Institute for OneWorld Health.
    [Google Scholar]
  39. Brenzel L, Wolfson LJ, Fox-Rushby J, Miller M, Halsey NA, 2006. Vaccine-preventable diseases.Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P eds. Disease Control Priorities in Developing Countries. Second edition. Washington, DC: World Bank, Chap. 20.
    [Google Scholar]
  40. Lee BY, Norman BA, Assi TM, Chen SI, Bailey RR, Rajgopal J, Brown ST, Wiringa AE, Burke DS, 2010. Single versus multi-dose vaccine vials: an economic computational model. Vaccine 28: 52925300.[Crossref]
    [Google Scholar]
  41. PACIFIC Exchange Rate Service, 2010. Today's Exchange Rates: Thursday, June 3, 2010. Vancouver: Bank of Canada.
    [Google Scholar]
  42. Shepard DS, 1999. Cost-effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. New York: Oxford University Press. J Ment Health Policy Econ 2: 9192.[Crossref]
    [Google Scholar]
  43. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377383.[Crossref]
    [Google Scholar]
  44. Singh UK, Prasad R, Jaiswal BP, Singh PK, Thakur CP, 2010. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial. J Trop Pediatr 47: 749751.
    [Google Scholar]
  45. World Health Organization, 2004. Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Geneva: World Health Organization.
    [Google Scholar]
  46. World Health Organization, 2010. Health statistics and health information systems: Disability weights, discounting and age weighting of DALYs. Available at: http://www.who.int/healthinfo/global_burden_disease/daly_disability_weight/en/index.html. Accessed May 25, 2010.
    [Google Scholar]
  47. Lopez AD, Ezzati M, Jamison DT, Murray CJL, 2006. Global Burden of Disease and Risk Factors. Washington, DC: The World Bank and Oxford University Press.[Crossref]
    [Google Scholar]
  48. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512.[Crossref]
    [Google Scholar]
  49. Croft SL, Sundar S, Fairlamb AH, 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111126.[Crossref]
    [Google Scholar]
  50. Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, Rijal S, Das P, Rowland M, Sundar S, Coosemans M, Boelaert M, Davies CR, 2010. Effect of village-wide use of long-lasting insecticidal nets on visceral leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis 4: e587.[Crossref]
    [Google Scholar]
  51. Mathur P, Samantaray JC, Vajpayee M, Samanta P, 2006. Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics. J Med Microbiol 55: 919922.[Crossref]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.10-0415
Loading
/content/journals/10.4269/ajtmh.2012.10-0415
Loading

Data & Media loading...

  • Received : 22 Jul 2010
  • Accepted : 27 Nov 2011
  • Published online : 01 Mar 2012
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error